Coronavirus Drug Update: The Latest Info On Pharmaceutical Treatments And Vaccines (Forbes website - Mar 13, 2020)
OPINION: Parang tayo yun saling pusa sa group project....bigyan naten sila ng kahit MORAL SUPPORT!!!!
Gilead Sciences
For the past few years, Foster City, California-based Gilead has been developing Remdesivir, an anti-viral that’s shown promising results in lab and animal studies against SARS, MERS, Ebola and other infectious diseases, including COVID-19. The company has You do not have permission to view the full content of this post. Log in or register now. in the U.S. and China to see if the drug can be effective against the new coronavirus, and also working with governments to provide the drug as an emergency treatment in the absence of other options.
Status: Large-scale human testing
Of note: A World Health Organization assessment from February described remdesivir as the “most promising candidate” against COVID-19.
AbbVie
AbbVie manufactures the co-formulation lopinavir/ritonavir, which is used to treat HIV. It’s currently You do not have permission to view the full content of this post. Log in or register now. to see if it can be used as a treatment against COVID-19, based on unconfirmed reports in China that its use was helpful in combating it. It has provided the drug to several countries, including China, as an experimental option.
Status: Working with health authorities such as the CDC, WHO, and the National Institutes of Health regarding testing.
Moderna
Cambridge, MA-based biotech startup Moderna has You do not have permission to view the full content of this post. Log in or register now. against COVID-19. The vaccine was developed in collaboration with scientists at the National Institute of Allergy and Infectious Diseases. The vaccine works by getting the immune system to develop antibodies against a You do not have permission to view the full content of this post. Log in or register now. found on the virus. A batch of the vaccine has been manufactured and delivered to the NIAID for a first round of testing.
Status: Phase 1 testing
Of note: The vaccine was developed, manufactured and sent out for testing just 42 days after the coronavirus DNA sequence was first published.
Johnson & Johnson
Pharmaceutical giant Johnson & Johnson You do not have permission to view the full content of this post. Log in or register now. with the Biomedical Advanced Research and Development Authority, a federal agency that helps develop countermeasures to biological threats, to develop potential vaccines and treatments for COVID-19. The company is working to identify molecules in its libraries that might be effective against the disease. It’s also leveraging technologies that were used to successfully develop an ebola vaccine towards finding promising vaccine candidates.
Status: Investigation and development
Of note: In addition to looking at new therapies, Johnson & Johnson has sent batches of its HIV drug darunavir/cobicistat to China to test its efficacy against COVID-19.
Eli Lilly
Indiana-based pharmaceutical company Eli Lilly You do not have permission to view the full content of this post. Log in or register now. it is partnering with Vancouver-based biotech firm AbCellera to co-develop antibody-based treatments against COVID-19. The firms have already discovered “hundreds” of antibodies that might be effective against the disease, with the next step being to screen those for the most effective treatment candidate.
Status: Screening antibody candidates to move to testing phase
Of note: "In 11 days, we've discovered hundreds of antibodies against the SARS-CoV-2 virus responsible for the current outbreak,” AbCellera CEO Carl Hansen said in a statement.
Pfizer
Earlier this month, You do not have permission to view the full content of this post. Log in or register now. that it had discovered several promising antiviral molecules that stop the SARS-CoV-2 virus from reproducing in cells in the lab. The candidates are currently being screened to identify the best candidates to move into the development pipeline. The company’s Chief Science Officer, Mikael Dolsten, You do not have permission to view the full content of this post. Log in or register now. might also consider exploring the combination of these molecules with antiviral treatments developed by other firms.
Status: Early development
Of note: On Friday, You do not have permission to view the full content of this post. Log in or register now. that part of its plan to combat COVID-19 would be sharing its expertise with smaller biotech companies and committed to using its excess manufacturing capacity to scale up any approved therapy or vaccine.
GlaxoSmithKline
GSK has previously developed a pandemic vaccine You do not have permission to view the full content of this post. Log in or register now. platform, a system that helps to improve vaccines by strengthening the immune response in patients who receive it. In February, the You do not have permission to view the full content of this post. Log in or register now. it was partnering with the Coalition for Epidemic Preparedness Innovations to use that platform to improve potential vaccines to the new coronavirus. As part of that collaboration, it signed an agreement with the University of Queensland, Australia, which is developing a potential vaccine. GSK has You do not have permission to view the full content of this post. Log in or register now. with Chinese pharmaceutical company Clover to use its adjuvant platform with that company’s COVID-19 vaccine candidate.
Status: Vaccines are still in early testing
Regeneron Pharmaceuticals
The New York-based biotechnology company is expanding its collaboration with the Department of Health and Human Services, which has already resulted in a potential ebola treatment. In that collaboration, the company is looking to identify potential antibody therapies that could be useful against COVID-19.
Status: Early Stage
Of note: Sarilumab, a rheumatoid arthritis treatment Regeneron developed with Sonfi, is You do not have permission to view the full content of this post. Log in or register now. to be tested as a potential COVID-19 treatment.
Inovio Pharmaceuticals
Pennsylvania-based pharmaceutical company Inovio Pharmaceuticals has announced it has You do not have permission to view the full content of this post. Log in or register now. for its vaccine candidate INO-4800. The company has previously developed a vaccine for MERS that’s in the testing phase. It’s also been You do not have permission to view the full content of this post. Log in or register now. to scale up the smart device it plans to use for the delivery of the vaccine. According to a statement, the company’s CEO has said it could begin human testing of the vaccine in April.
Status: In development, with testing to begin soon
Vir Biotechnology
San Francisco-based Vir Biotechnology announced March 12 that it’s going to be You do not have permission to view the full content of this post. Log in or register now. to manufacture antibodies that may have potential to treat COVID-19. The company has identified antibodies from people who recovered from SARS, and is studying to see if they might be active against the new coronavirus, as the two are very similar. Vir is also working with federal agencies to advance its research against other coronaviruses.
Status: Early stage
Of note: In February, Vir You do not have permission to view the full content of this post. Log in or register now. Chinese pharmaceutical firm WuXi Biologics on this research as well.
Sanofi
French pharmaceutical company Sanofi You do not have permission to view the full content of this post. Log in or register now. with BARDA to expedite a COVID-19 vaccine, leveraging technology already in use in development of a SARS vaccine. The company says that it will use its recombinant DNA tech with an aim of finding an exact genetic match to the surface proteins of the virus.
Status: Vaccine is in development
Of note: Sarilumab, a rheumatoid arthritis treatment Sanofi developed with Regeneron, is You do not have permission to view the full content of this post. Log in or register now. to be tested as a potential COVID-19 treatment.
OPINION: Parang tayo yun saling pusa sa group project....bigyan naten sila ng kahit MORAL SUPPORT!!!!
Gilead Sciences
For the past few years, Foster City, California-based Gilead has been developing Remdesivir, an anti-viral that’s shown promising results in lab and animal studies against SARS, MERS, Ebola and other infectious diseases, including COVID-19. The company has You do not have permission to view the full content of this post. Log in or register now. in the U.S. and China to see if the drug can be effective against the new coronavirus, and also working with governments to provide the drug as an emergency treatment in the absence of other options.
Status: Large-scale human testing
Of note: A World Health Organization assessment from February described remdesivir as the “most promising candidate” against COVID-19.
AbbVie
AbbVie manufactures the co-formulation lopinavir/ritonavir, which is used to treat HIV. It’s currently You do not have permission to view the full content of this post. Log in or register now. to see if it can be used as a treatment against COVID-19, based on unconfirmed reports in China that its use was helpful in combating it. It has provided the drug to several countries, including China, as an experimental option.
Status: Working with health authorities such as the CDC, WHO, and the National Institutes of Health regarding testing.
Moderna
Cambridge, MA-based biotech startup Moderna has You do not have permission to view the full content of this post. Log in or register now. against COVID-19. The vaccine was developed in collaboration with scientists at the National Institute of Allergy and Infectious Diseases. The vaccine works by getting the immune system to develop antibodies against a You do not have permission to view the full content of this post. Log in or register now. found on the virus. A batch of the vaccine has been manufactured and delivered to the NIAID for a first round of testing.
Status: Phase 1 testing
Of note: The vaccine was developed, manufactured and sent out for testing just 42 days after the coronavirus DNA sequence was first published.
Johnson & Johnson
Pharmaceutical giant Johnson & Johnson You do not have permission to view the full content of this post. Log in or register now. with the Biomedical Advanced Research and Development Authority, a federal agency that helps develop countermeasures to biological threats, to develop potential vaccines and treatments for COVID-19. The company is working to identify molecules in its libraries that might be effective against the disease. It’s also leveraging technologies that were used to successfully develop an ebola vaccine towards finding promising vaccine candidates.
Status: Investigation and development
Of note: In addition to looking at new therapies, Johnson & Johnson has sent batches of its HIV drug darunavir/cobicistat to China to test its efficacy against COVID-19.
Eli Lilly
Indiana-based pharmaceutical company Eli Lilly You do not have permission to view the full content of this post. Log in or register now. it is partnering with Vancouver-based biotech firm AbCellera to co-develop antibody-based treatments against COVID-19. The firms have already discovered “hundreds” of antibodies that might be effective against the disease, with the next step being to screen those for the most effective treatment candidate.
Status: Screening antibody candidates to move to testing phase
Of note: "In 11 days, we've discovered hundreds of antibodies against the SARS-CoV-2 virus responsible for the current outbreak,” AbCellera CEO Carl Hansen said in a statement.
Pfizer
Earlier this month, You do not have permission to view the full content of this post. Log in or register now. that it had discovered several promising antiviral molecules that stop the SARS-CoV-2 virus from reproducing in cells in the lab. The candidates are currently being screened to identify the best candidates to move into the development pipeline. The company’s Chief Science Officer, Mikael Dolsten, You do not have permission to view the full content of this post. Log in or register now. might also consider exploring the combination of these molecules with antiviral treatments developed by other firms.
Status: Early development
Of note: On Friday, You do not have permission to view the full content of this post. Log in or register now. that part of its plan to combat COVID-19 would be sharing its expertise with smaller biotech companies and committed to using its excess manufacturing capacity to scale up any approved therapy or vaccine.
GlaxoSmithKline
GSK has previously developed a pandemic vaccine You do not have permission to view the full content of this post. Log in or register now. platform, a system that helps to improve vaccines by strengthening the immune response in patients who receive it. In February, the You do not have permission to view the full content of this post. Log in or register now. it was partnering with the Coalition for Epidemic Preparedness Innovations to use that platform to improve potential vaccines to the new coronavirus. As part of that collaboration, it signed an agreement with the University of Queensland, Australia, which is developing a potential vaccine. GSK has You do not have permission to view the full content of this post. Log in or register now. with Chinese pharmaceutical company Clover to use its adjuvant platform with that company’s COVID-19 vaccine candidate.
Status: Vaccines are still in early testing
Regeneron Pharmaceuticals
The New York-based biotechnology company is expanding its collaboration with the Department of Health and Human Services, which has already resulted in a potential ebola treatment. In that collaboration, the company is looking to identify potential antibody therapies that could be useful against COVID-19.
Status: Early Stage
Of note: Sarilumab, a rheumatoid arthritis treatment Regeneron developed with Sonfi, is You do not have permission to view the full content of this post. Log in or register now. to be tested as a potential COVID-19 treatment.
Inovio Pharmaceuticals
Pennsylvania-based pharmaceutical company Inovio Pharmaceuticals has announced it has You do not have permission to view the full content of this post. Log in or register now. for its vaccine candidate INO-4800. The company has previously developed a vaccine for MERS that’s in the testing phase. It’s also been You do not have permission to view the full content of this post. Log in or register now. to scale up the smart device it plans to use for the delivery of the vaccine. According to a statement, the company’s CEO has said it could begin human testing of the vaccine in April.
Status: In development, with testing to begin soon
Vir Biotechnology
San Francisco-based Vir Biotechnology announced March 12 that it’s going to be You do not have permission to view the full content of this post. Log in or register now. to manufacture antibodies that may have potential to treat COVID-19. The company has identified antibodies from people who recovered from SARS, and is studying to see if they might be active against the new coronavirus, as the two are very similar. Vir is also working with federal agencies to advance its research against other coronaviruses.
Status: Early stage
Of note: In February, Vir You do not have permission to view the full content of this post. Log in or register now. Chinese pharmaceutical firm WuXi Biologics on this research as well.
Sanofi
French pharmaceutical company Sanofi You do not have permission to view the full content of this post. Log in or register now. with BARDA to expedite a COVID-19 vaccine, leveraging technology already in use in development of a SARS vaccine. The company says that it will use its recombinant DNA tech with an aim of finding an exact genetic match to the surface proteins of the virus.
Status: Vaccine is in development
Of note: Sarilumab, a rheumatoid arthritis treatment Sanofi developed with Regeneron, is You do not have permission to view the full content of this post. Log in or register now. to be tested as a potential COVID-19 treatment.
)